Small molecule · Inhibitor of CD73 (NT5E) · developed by ORIC Pharmaceuticals
ORIC-533 is an orally bioavailable inhibitor of CD73, an ectoenzyme that converts adenosine monophosphate to adenosine in the tumor microenvironment. By blocking CD73, the drug reduces adenosine-mediated immunosuppression, enhancing CD8+ T cell and NK cell activity while reducing regulatory T cells and myeloid-derived suppressor cells. It is studied in relapsed or refractory multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05227144 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Completed | ORIC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed or Refractory Multiple Myeloma
Updated Oct 3, 2026. Something wrong or missing? Report it on the ORIC page.
See ORIC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ORIC catalysts and pipeline →